Written and maintained by CASRAI Editorial Board
Last updated
Short answer: Phage display is a laboratory selection technique in which peptides or antibody fragments are fused to a coat protein of a bacteriophage, most often the filamentous M13 phage, so that each phage particle carries a binding molecule on its surface and the gene encoding it inside. Repeated rounds of binding, washing and amplification (biopanning) pull out binders from libraries of billions of variants. It is a discovery tool, not a treatment.
This page is general educational information for researchers and laboratory staff. It is not a protocol and not medical advice.
Definition and scope
The defining feature is the physical link between phenotype and genotype. The displayed protein is what binds the target; the DNA packaged in the same particle is what lets you identify and amplify it after selection (Ledsgaard et al., 2018). The method was introduced by George Smith in 1985, who displayed peptides fused to the gene III coat protein; McCafferty and colleagues extended it in 1990 to single-chain Fv antibody fragments displayed on gene III. The 2018 Nobel Prize in Chemistry recognised Smith’s development of phage display and Gregory Winter’s use of it for the directed evolution of antibodies, and the announcement notes that the first drug based on the method, adalimumab, was approved in 2002.
M13 phage: what it is and why it is the usual platform
The searches “bacteriophage M13”, “M13 phage” and “phage M13” all point to the same particle. According to Ledsgaard et al. (2018), M13 is a filamentous phage about 900 nm long and 6.5 nm wide, with a single-stranded DNA genome of 6407 bp encoding 11 proteins from nine genes. Which coat protein you fuse your molecule to determines how many copies are displayed:
| M13 protein | Role | Approximate copies per particle |
|---|---|---|
| G8P (pVIII) | Major coat protein forming the envelope | about 2700 |
| G3P (pIII) | Minor coat protein; the usual fusion partner for antibody fragments | 3 to 5 |
| G6P, G7P, G9P | Minor coat proteins | about 5 each |
The copy numbers matter for experimental design: a fusion to G3P presents few copies per particle, whereas G8P is present in thousands of copies. The same source describes antibody-G3P fusions in a full phage vector as potentially multivalent.
How biopanning works
At concept level, one selection cycle has five steps (Ledsgaard et al., 2018): the library is added to the target (antigen), binders attach, non-binding phage are washed away, bound phage are eluted (for example with trypsin or another method), and the eluted phage are amplified in E. coli with helper phage. The cycle is usually repeated one to three times, enriching for stronger binders. Amplification relies on bacterial culture; see protein expression in E. coli for the host-side background.
Library and vector types compared
Every row below is taken from Ledsgaard et al. (2018).
| Option | What it is | Trade-off reported |
|---|---|---|
| Phage vector | Antibody gene cloned directly into the phage genome | Potentially multivalent display; the article reports a wider range of antibody affinities |
| Phagemid | Small plasmid with antibiotic marker, antibody-G3P gene and phage origin; needs helper phage | Higher transformation efficiency, so larger libraries; more commonly used |
| Naive library | Built from non-immunized donors, often IgM | Wide antigen range; fragments generally lower affinity |
| Immunized library | Built from immunized donors, often IgG | Higher affinity for the immunizing antigen through in vivo maturation; less diverse and less broadly applicable |
What are the applications of antibody phage display?
Antibody phage display is used to discover antibody fragments against a chosen target. Ledsgaard et al. (2018) describe antibody discovery as important in almost all areas of modern medicine and focus on toxinology, including recombinant antivenom research against snake, scorpion and bee toxins. The Nobel announcement cites adalimumab as an approved drug based on the method. Peptide display, as in Smith’s original work, applies the same selection logic to short peptides. Selected antibody fragments are typically then characterised in assays such as those described in ELISA antibodies: capture, detection and matched pairs and, for later-stage biologics, immunogenicity testing such as anti-drug antibody assays.
Where it matters for labs
For a lab deciding whether phage display fits a project, the sourced decision points are: whether you need breadth (naive library) or affinity to a known immunogen (immunized library); whether library size matters most (phagemid) or multivalent display (phage vector); and whether you will test function after selection. A selection-is-not-function checklist:
- Binding in a biopanning round does not establish activity. Ledsgaard et al. state that binding does not necessarily translate into toxin-neutralizing ability in vivo, so selected clones need functional testing.
- Library origin shapes what you can find: naive libraries trade affinity for breadth; immunized libraries do the reverse.
- Phagemid systems depend on helper phage for packaging, a reagent and workflow requirement to plan for.
Common misunderstandings
Phage display is not phage therapy
Phage display uses a phage as a carrier to select binding molecules in the laboratory. Phage therapy uses phages to treat bacterial infection and is a separate topic regulated differently. For regulatory status of phage therapy, consult the FDA’s own pages on bacteriophage therapy rather than this page. See bacteriophage T4 for another phage model system.
Not all phages look like M13
M13 is a long, thin filament. The icosahedral head with a tail that people picture, and that can look engineered, belongs to tailed phages such as T4, not to M13.
FAQ
What are the applications of the antibody phage display technique?
Discovering antibody fragments against a target from very large libraries, including antivenom research and the development of therapeutic antibodies such as adalimumab (approved 2002, per the Nobel announcement).
Is phage therapy legal in the US?
That is a question about phage therapy, not phage display. Phage display is a laboratory research technique. For the regulatory status of phage therapy, see the FDA’s pages on bacteriophage therapy.
What is a high phage titer?
Titer is the concentration of infectious phage particles in a preparation. What counts as high depends on the phage, the host and the purpose, and this page does not set a threshold; follow the protocol or kit documentation for your system.
Why do bacteriophages look so man-made?
The head-and-tail form comes from tailed phages such as T4. M13, the phage used for most display work, is instead a filament about 900 nm long and 6.5 nm wide.
Sources
- Ledsgaard L, Kilstrup M, Karatt-Vellatt A, McCafferty J, Laustsen AH. Basics of Antibody Phage Display Technology. Toxins (Basel) 2018;10(6):236. doi:10.3390/toxins10060236. PMC6024766, read 2026-11-07.
- The Nobel Prize in Chemistry 2018, press release (NobelPrize.org, 3 Oct 2018), as reproduced by RCSB, read 2026-11-07.
